Declaration of Financial Results ( Consolidated and Standalone) for the quarter and year ended March 31, 2026
MANGALAM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Mangalam Drugs and Organics Limited reported a massive turnaround from profit to loss for FY2026. Standalone revenue declined 27% to Rs 2,321.27 lakhs from Rs 3,175.76 lakhs in FY2025. The company posted a standalone net loss of Rs 4,381.42 lakhs compared to a net profit of Rs 692.43 lakhs in the previous year. Consolidated net loss stood at Rs 3,440 lakhs. Despite the losses, operating cash flow remained positive at Rs 416.45 lakhs (standalone) and Rs 417.76 lakhs (consolidated). Borrowings increased significantly with current borrowings rising to Rs 9,455.80 lakhs from Rs 7,095.51 lakhs. Inventories reduced from Rs 13,880 lakhs to Rs 10,277 lakhs indicating lower sales volume. The auditors issued an unqualified opinion with no modifications.
The company swung from a profit of Rs 692 lakhs to a loss of Rs 4,381 lakhs, representing a catastrophic decline. Revenue dropped 27% and margins compressed severely. Increased borrowing and declining equity base raise concerns about financial health. The stock faces significant negative sentiment.